Prot #NU 23H05: Phase II, Single arm, Open label, study of the combination of Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following Autologous Stem Cell Transplantation (ASCT) or Chimeric Antigen Receptor (CAR) T-cell therapy in Patients

Project: Research project

Project Details

StatusActive
Effective start/end date9/23/24 → 9/23/27

Funding

  • Merck Sharp & Dohme LLC (Prot #NU 23H05)